Interstitial Lung Disease Research Unit Biobank

Idiopathic Pulmonary Fibrosis Clinical Trial

— ILDRU  

Official title:

University of Kansas Medical Center Interstitial Lung Disease Research Unit (ILDRU) Biobank

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05392881
• Other study ID #: STUDY00144558
• Status: Recruiting
• Start date: August 9, 2021
• Est. completion date: March 1, 2032

Study information

• Verified date: November 2023
• Source: University of Kansas Medical Center
• Contact: Kimberly Donnelly, Ph.D.
• Phone: 913-588-6067
• Email: kdonnelly[@]kumc.edu
• Is FDA regulated: No
• Study type: Observational [Patient Registry]

Clinical Trial Summary

Establish a interstitial lung disease (ILD) registry and biorepository to lead towards a further understanding of the disease.

Description:

The University of Kansas ILD and Rare Lung Disease clinic sees hundreds of new patients per year. The investigators would like to leverage this resource to develop an Interstitial Lung Disease Research Unit (ILDRU) repository and database to help develop new methods for early diagnosis, uncover underlying genetic and environmental risk factors, as well as potential treatment targets in the broad range of interstitial lung diseases and rare lung diseases (RLD).

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 1000
• Est. completion date: March 1, 2032
• Est. primary completion date: August 1, 2031
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. The participant is a patient at TUKHS or has agreed to participate in a study approved by the KUMC Human Research Protection Program (HRPP)

2. The participant is being followed for the presence of autoimmune disease, ILD or other rare lung diseases at TUKHS.

3. The participant is = 18 years of age.

4. The participant has signed an approved consent for this study (living patients only)

Related Conditions & MeSH terms

• Alveolitis, Extrinsic Allergic
• Fibrosis
• Hypersensitivity
• Hypersensitivity Pneumonitis
• Idiopathic Pulmonary Fibrosis
• Interstitial Lung Disease
• Lung Diseases
• Lung Diseases, Interstitial
• Pneumonia
• Pulmonary Fibrosis
• Sarcoidosis

Locations

Country	Name	City	State
United States	The University of Kansas Medical Center	Kansas City	Kansas

Sponsors (1)

Lead Sponsor	Collaborator
University of Kansas Medical Center

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Collect clinically obtained data for patients with ILD, RLD and risk for ILD/RLD to support research.		Enrollment to Year 10
Primary	Establish a collection of biological samples from patients with ILD, RLD and subjects at risk for ILD.		Enrollment to Year 10
Primary	Correlate biological samples with individual longitudinal clinical data.		Enrollment to Year 10
Primary	Provide biological samples to researchers performing studies in ILD and RLD.		Enrollment to Year 10
Primary	Collect historical data and imaging from deceased patients with ILD.		Enrollment to Year 10